The United Kingdom and the United States have established a important bilateral deal that will guarantee zero tariffs on UK pharmaceutical exports going into the US market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these key exports will remain at nothing for a timeframe of three years.
This development is in response to earlier warnings to dramatically increase import taxes on branded drug products, with increases mentioned as high as 100%.
"This arrangement with the United Kingdom bolsters the global environment for new treatments and establishes long-overdue balance to transatlantic medicine commerce," a statement said.
Commercial Significance
Medicines are one of the UK's biggest export categories to the America, which is easily the biggest destination for large UK drugmakers.
Trade data show that in the year prior to September, the UK sold drugs worth billions to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This guarantee secures jobs, increases investment and paves the way for the UK to become a worldwide center for life sciences," a minister remarked.
Specific NHS Changes
The agreement includes several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to double overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must refund to the NHS to stay within budget will be restricted at fifteen percent. Last year, rebates were more than twenty percent.
Industry Background
The deal takes place against a ongoing dispute between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
The disagreement were exacerbated by arguments that American customers were paying several times more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been paused or cancelled, while substantial funding commitments have been announced toward US facilities.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had declined as a share of its overall budget over the past decade.
